Costs of resolving a ureteral or kidney stone episode worldwide: a systematic review.

PURPOSE

This systematic review compares the costs of common urolithiasis surgical options worldwide, identifies sources of heterogeneity in cost reporting, and propose recommendations for standardizing economic evaluations with the aim of reducing urolithiasis' financial burden globally.

METHODS

We systematically searched Medline, EMBASE and Web of Science for studies published between 2014 and 2024. Included studies involved adult patients treated for a urolithiasis, described components of cost calculations, and provided a monetary value. Data was summarized qualitatively, and costs were first inflated, then converted to 2024 USD for comparability.

RESULTS

After identifying 2,461 references, 38 studies from 13 countries met the inclusion criteria. Variations in the definition of stone-free status were noted, with 17 studies not specifying it at all. While most studies accounted for procedural and hospital stay costs, the rest of the cost calculation components varied significantly. The costs of managing an episode with URS ranged from 249.12 to 48,937 USD, as for ESWL, the costs ranged from 177.48 to 10,184.64 USD. The costs of managing an episode using PCNL presented the largest disparity, ranging from 164.89 to 101,510.23 USD. Finally, studies assessing the management using MET reported costs from 293.89 to 17,982.19 USD.

CONCLUSION

Our review highlights substantial variability in urolithiasis treatment costs worldwide. Standardizing cost calculation methods and clinical success definitions is critical for guiding cost-effective decision-making and supporting evidence-based strategies to optimize resource allocation and reduce urolithiasis' financial burden globally.